NASDAQ NMS - GLOBAL MARKET · IMA
-7.59% · -$0.3500 · Vol 30.1K
Market closed · last close 4:00 PM ET · price as of 16:00:00 ET
ImageneBio Inc

ImageneBio Inc

Pharmaceuticals
$4.26
Card
Relationship Map

Follow $IMA

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $IMA by email

Veridion Score

BETAMEDIUM CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
IMA
ImageneBio Inc
Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Lower range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

39/ 100
Veridion Score
Lower range · MEDIUM confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 5 of 6 factors measured · Thu Oct 8 · market closed · Markets closed · resumes Fri 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is IMA moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading IMA catalysts
About ImageneBio Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2025
Employees
18
Country
US

ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$4.48
Day high
$4.48
Day low
$4.00
Previous close
$4.61
52W high
$8.79
-51.54% from high
52W low
$4.00
5% of range
Market cap
$52.3M
EPS
$-4.5900
Beta
0.84
Shares out
11.4M
Volume
30.1K
1.92× rel vol
Avg volume
15.7K
VWAP
$4.22
Price history computed in-house
1W
-7.39%
1M
-14.97%
3M
-27.92%
1Y
-48.24%
YTD
-38.26%
SMA 50 $5.18 · below
SMA 200 $5.83 · below
52W position 5%

IMA overview

Veridion Score
39
Registered · 2026-10-08
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around IMA.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading IMA Form 4 filings
Public disclosures

Congress activity in IMA

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

IMA contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for IMA in this window.
Lobbying spend

IMA lobbying filings, year to date.

Registered lobbying filings matched to ImageneBio Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for IMA in this window.
Loading news for IMA
Analyst ratings
Sovereign unlock shows live analyst consensus for IMA.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.